Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Prexige Is “Not Approvable;” COX-2 Launch At Least Two Years Away

Executive Summary

The liver safety profile of Novartis' Prexige appears to be one factor behind FDA's request for additional studies on the COX-2 inhibitor prior to approval in osteoarthritis and acute pain
Advertisement

Related Content

Novartis’ Prexige withdrawn in Australia
Novartis’ Prexige withdrawn in Australia
Novartis Is Confident In Prexige’s Prospects Despite Arcoxia AC Debacle
Novartis Prexige NDA Re-Submission Expected In 2006; TARGET Data “Clean”
COX-2, NSAID Concomitant Use With GI Protective Drugs Is Similar, Study Says
Novartis R&D Portfolio Grows 44% Since 2000; Half Of Projects Are NMEs
Novartis Sales Growth Strategy Is DTC Ads, “Cleverly Crafted” Phase IVs
Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events
Merck revises Arcoxia NDA
Novartis COX-189 TARGET Study Will Assess CV Safety Of COX-2 Inhibitor
Advertisement
UsernamePublicRestriction

Register

PS042543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel